ACM
BIIB icon

Atlanta Capital Management’s Biogen BIIB Stock Holding History

Atlanta Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-38,713
Closed -$10.6M – 151
2017
Q1 		$10.6M Sell
38,713
-4,722
-11% -$1.34M 0.07% 147
2016
Q4 		$12.3M Sell
43,435
-23,615
-35% -$7M 0.08% 145
2016
Q3 		$21M Sell
67,050
-212,574
-76% -$63M 0.14% 133
2016
Q2 		$67.6M Sell
279,624
-58,856
-17% -$15.5M 0.45% 68
2016
Q1 		$88.1M Buy
338,480
+25,014
+8% +$6.61M 0.63% 54
2015
Q4 		$96M Buy
313,466
+27,575
+10% +$7.92M 0.7% 55
2015
Q3 		$83.4M Buy
285,891
+12,195
+4% +$4.03M 0.63% 60
2015
Q2 		$111M Buy
273,696
+163,112
+148% +$65.5M 0.75% 57
2015
Q1 		$46.7M Buy
110,584
+45,199
+69% +$17.8M 0.32% 98
2014
Q4 		$22.2M Sell
65,385
-58,909
-47% -$19.1M 0.15% 139
2014
Q3 		$41.1M Buy
+124,294
New +$41M 0.3% 96

Other funds holding BIIB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Atlanta Capital Management's BIIB Position: Q2 2017 in Review

Atlanta Capital Management sold out of Biogen (BIIB) in Q2 2017, closing a stake of 38,713 shares — an estimated $10.6M sold.

Atlanta Capital Management first reported a position in BIIB in Q3 2014 and held it in 11 quarters. The position peaked at $111M in Q2 2015. 993 funds tracked by Wall St. Rank hold BIIB as of Q2 2017.

  • Atlanta Capital Management reported no remaining Biogen position as of Q2 2017 after selling out during the quarter.
  • Atlanta Capital Management sold 38,713 Biogen shares in Q2 2017, an estimated $10.6M.
  • Atlanta Capital Management first reported a position in Biogen in Q3 2014 and held it in 11 quarters.
  • Atlanta Capital Management's Biogen position peaked at $111M in Q2 2015.
  • 993 funds tracked by Wall St. Rank held Biogen as of Q2 2017.

Based on Atlanta Capital Management's 13F filing for Q2 2017, filed 15 Aug 2017.